## Contents

**REVIEW**

396  Sleep, health behaviors, and behavioral interventions: Reducing the risk of cardiovascular disease in adults  
*Kaar JL, Luberto CM, Campbell KA, Huffman JC*

**MINIREVIEWS**

407  Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk  
*Cahill TJ, Kharbanda RK*

416  Transcervical access, reversal of flow and mesh-covered stents: New options in the armamentarium of carotid artery stenting  
*Paraskevas KI, Veith FJ*

422  Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature  
*Battipaglia I, O'Neill J, Hogarth AJ, Tayebjee MH*

429  Antitachycardia pacing programming in implantable cardioverter defibrillator: A systematic review  
*De Maria E, Giacopelli D, Borghi A, Modonesi L, Cappelli S*

**ORIGINAL ARTICLE**

437  Clinical characteristics and outcomes of octogenarians presenting with ST elevation myocardial infarction in the Australian population  
*Sim WL, Mutha V, Ul-Haq MA, Sasongko V, Van-Gaal W*

**Retrospective Study**

442  Jailing polymer jacketed guide-wires during bifurcation coronary interventions is associated with procedural myocardial infarction  
*Chatterjee A, White JS, Hashim T, Leesar MA*

**Observational Study**

448  Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients  
*Tetzlaff WF, Meroño T, Menafra M, Martin M, Botta E, Matoso MD, Sorroche P, De Paula JA, Boero LE, Brites F*
Prospective Study

457 Combined assessment of myocardial damage and electrical disturbance in chronic heart failure

Kadowaki S, Watanabe T, Otaki Y, Narumi T, Honda Y, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Kubota I

CASE REPORT

466 Cough induced syncope: A hint to cardiac tamponade diagnosis

Ramirez R, Lasam G
Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients

Walter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Maria D Matoso, Patricia Sorroche, Juan A De Paula, Laura E Boero, Fernando Brites

AIM
To evaluate novel risk factors and biomarkers of cardiovascular disease in celiac disease (CD) patients compared with healthy controls.

METHODS
Twenty adult patients with recent diagnosis of CD and 20 sex, age and body mass index-matched healthy controls were recruited during a period of 12 mo. Indicators of carbohydrate metabolism, hematological parameters and high sensitive C reactive protein were determined. Moreover, lipoprotein metabolism was also explored through evaluation of the lipid profile and...
the activity of cholesteryl ester transfer protein and lipoprotein associated phospholipase A2, which is also considered a specific marker of vascular inflammation. The protocol was approved by the Ethic Committee from School of Pharmacy and Biochemistry, University of Buenos Aires and from Buenos Aires Italian Hospital, Buenos Aires, Argentina.

RESULTS
Regarding the indicators of insulin resistance, CD patients showed higher plasma insulin levels [7.2 (5.0-11.3) μU/L vs 4.6 (2.6-6.7) μU/L, P < 0.05], increased Homeostasis Model Assessment-Insulin Resistance [1.45 (1.04-2.24) vs 1.00 (0.51-1.45), P < 0.05] and lower Quantitative Sensitive Check index [0.33 (0.28-0.40) vs 0.42 (0.34-0.65), P < 0.05] indexes. Folic acid concentration [5.4 (4.4-7.9) ng/mL vs 12.2 (8.0-14.2) ng/mL, P < 0.01] resulted to be lower and High-sensitivity C reactive protein levels higher (4.21 ± 6.47 mg/L vs 0.98 ± 1.13 mg/L, P < 0.01) in the patient group. With respect to the lipoprotein profile, CD patients showed lower high density lipoprotein-cholesterol (HDL-C) (45 ± 15 mg/dL vs 57 ± 17 mg/dL, P < 0.05) and apo A-I (130 ± 31 mg/dL vs 155 ± 29 mg/dL, P < 0.05) levels, as well as higher total cholesterol/ HDL-C [4.19 (3.11-5.00) vs 3.52 (2.84-4.08), P < 0.05] and apo B/apo A-I (0.75 ± 0.25 vs 0.55 ± 0.16, P < 0.05) ratios in comparison with control subjects. No statistically significant differences were detected in lipoprotein-associated lipid transfer protein and enzymes.

CONCLUSION
The presence and interaction of the detected alterations in patients with CD, would constitute a risk factor for the development of atherosclerotic cardiovascular disease.

Key words: Inflammation; Cardiovascular disease; High density lipoprotein-cholesterol; Lipoproteins; Celiac disease

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Given that data about the presence of metabolic alterations and atherogenic risk factors in celiac disease are scarce and contradictory, we aimed to investigate carbohydrate metabolism, lipoprotein profile and inflammatory status in patients with celiac disease (CD). Patients presented higher insulin levels, Homeostasis Model Assessment-Insulin Resistance index, apo B/apo A-I ratio and High-sensitivity C reactive protein concentration, as well as lower Quantitative Sensitive Check index index, high density lipoprotein-cholesterol and apo A-I levels in comparison with sex and aged-matched healthy controls. Persistence of these alterations through long periods of time in a chronic pathologic condition, as it is the case with CD, would constitute a high risk of developing atherosclerotic cardiovascular disease.

INTRODUCTION
Celiac disease (CD) is a multisystemic disease which mainly affects the digestive system, though not exclusively. Its main trait is chronic and diffuse inflammation of the mucosa of the small intestine and it can present a wide variety of clinical symptoms[1]. Thus far, the only available therapy for CD consists of the implementation of a gluten free diet (GFD), whose efficacy depends on strict adherence.

It is remarkable that most cases of CD lack typical gastrointestinal symptoms and are, instead, very frequently associated with presentations known as atypical or extra-intestinal. Thus, its diagnosis represents one of the main challenges for health professionals[2].

Commonly, CD has been associated with certain physiopathological conditions (type 1 diabetes, Hashimoto thyroiditis, etc.) which are not directly related to gluten ingestion[3]. Among these conditions, it is worth noting that the evidence linking CD and atherosclerotic cardiovascular disease (CVD) is scarce. It is well known that CD patients do not show classical CVD risk factors. In fact, hypertension and hypercholesterolemia are less frequent in CD patients than in the general population[4]. However, previous studies have failed to show lower CVD risk in CD patients than in healthy subjects[5,6]. Furthermore, an important study carried out in Sweden in approximately 14000 hospitalized CD patients showed higher risk of acute myocardial infarction, chest angina, cardiac insufficiency, brain hemorrhage and ischemic stroke when compared to sex and age-paired healthy controls[7].

These facts suggest that CD would be associated with novel atherogenic risk factors or even with other non-identified risk factors. In fact, inflammation and anemia, among other signs that characterize CD, could represent a link between this pathology and CVD[7-8].

Atherosclerosis is presently understood as a chronic inflammatory disease in which endothelial dysfunction and biomarkers of inflammation are present since the early stages of the pathology[9]. So far, the inflammatory process typical of CD has not been described in relation to increased risk of CVD.

The aim of the present study was to evaluate novel risk factors and biomarkers of CVD in CD patients in comparison to sex, age and body mass index (BMI)-matched healthy controls. In addition, the metabolic differences between patients with typical and atypical presentations of the disease were also analyzed.
MATERIALS AND METHODS

Subjects
Twenty patients with CD were consecutively recruited from the service of gastroenterology, Buenos Aires Italian Hospital, during a period of 12 mo. The inclusion criteria were adult age and recent diagnosis of CD (<3 mo) based on histopathological findings and serological markers (anti-gliadin IgG and IgA and anti-transglutaminase IgA). Patients were not treated and they had not still started a GFD. All individuals presenting any other intestinal inflammatory disease, IgA deficiency, malignant diseases, chronic infections, pregnancy, thyroid, renal or hepatic alterations, history of CVD, smoking, alcohol consumption >40 g/d, and treatment with drugs known to affect lipid and/or carbohydrate metabolism were excluded. Patients were classified according to the presence of gastrointestinal (typical presentation) or extra-digestive symptoms (atypical presentation)[2]. Gastrointestinal manifestations analyzed were: Diarrhea, abdominal distention, weight loss, and malabsorption syndrome. Extra-digestive alterations considered were: Anemia, mouth ulcers, osteoporosis, and modifications of liver function tests. Employing these criteria, 11 out of the 20 CD patients showed gastrointestinal symptomatology and 9 showed only extradigestive symptoms. The group of CD patients was compared with a sex, age and BMI-matched group of healthy volunteers (n=20). Weight, height and waist circumference were registered in all subjects and an exhaustive anamnesis was performed. All participants in the study signed an informed consent. The protocol was approved by the Ethical Committees from School of Pharmacy and Biochemistry, University of Buenos Aires and from Buenos Aires Italian Hospital. Buenos Aires, Argentina.

Study protocol and samples
Blood samples were obtained from the antecubital vein after 12 h of fasting. Serum and EDTA plasma (final EDTA concentration 1 mg/mL) were prepared from venous blood collected into sterile, evacuated tubes. The former was centrifuged at 1500 g for 15 min at 4℃. Serum was isolated and stored at 4℃ and -70℃.

Determination of general biochemical parameters
Plasma concentrations of glucose, urea, uric acid, total bilirubin, folic acid and vitamin B12, as well as aspartate aminotransferase (ASAT), alanin aminotransferase and alkaline phosphatase activities, and hemogram were determined by standardized methods. Insulin levels were measured by radioimmunoassay (Diagnostics Products Corp., Los Angeles CA, United States). Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) was calculated using the formula [glucose (mmol/L) * insulin (mU/mL)] /22.5 and Quantitative Sensitive Check index (QUICKI) using the formula 1/[ln Glucose (mmol/L) + ln Insulin (mU/L)][10,11]. High-sensitivity C reactive protein (hsCRP) levels were determined by immunoturbidimetry (Roche, Mannheim, Germany) in a Hitachi 917 autoanalyzer (Tokyo, Japan).

Determination of the lipid, lipoprotein and apolipoprotein profile
Plasma levels of total cholesterol (TC) and triglycerides were quantified by standardized methods (Roche, Manheim, Germany) in a Hitachi 917 autoanalyzer (Tokyo, Japan). High density lipoproteins (HDL) were isolated from the supernatant obtained after selective precipitation of apolipoprotein (apo) B-containing lipoproteins using 0.44 mmol/L phosphotungstic acid in presence of magnesium ions[12]. Cholesterol (C) of low density lipoprotein (LDL) was estimated as the difference between TC and the cholesterol contained in the supernatant obtained after selective precipitation of LDL with 10 g/L polivinil sulfate in polyethileneglicol (600 Da; 2.5 w/v; pH = 6.7)[13]. Non HDL-C was calculated as the difference between TC and HDL-C. Very low density lipoprotein cholesterol (VLDL-C) was calculated as the difference between the supernatants of the LDL-C and HDL-C precipitations. Apo B and apo A-I levels were quantified by immunoturbidimetry (Roche, Manheim, Germany) in a Hitachi 917 autoanalyzer (Tokyo, Japan). Results were expressed as mg/dL. The following ratios were calculated: TG/HDL-C, TC/HDL-C and apo B/apo A-I.

Determination of cholesteryl ester transfer protein activity
Cholesteryl ester transfer protein (CETP) activity was evaluated in serum samples following the radiometric method previously described with minor modifications[14]. Briefly, the capacity of the serum to promote the transfer of tritiated esterified cholesterol (EC) from the biosynthetically marked HDL3 subfraction ([3H-EC-HDL3]) to apo B-containing lipoproteins present in the serum. Serum samples were incubated with [3H-CE-HDL3] (50 µmol/L cholesterol) with iodoacetate (1.5 mmol/L) in TBS buffer (pH = 7.4) during 3 h at 37℃. After incubation, apo B-containing lipoproteins were separated from HDL by selective precipitation with phosphotungstic acid (0.44 mmol/mL) in the presence of magnesium ions. Radioactivity was measured in the reaction cocktail and in the supernatant containing the HDL subfraction in a liquid scintillation counter (Packard 210 TR, Packard Instruments, Meridians, CT, United States). Results were expressed as the percentage of tritiated EC transferred from HDL3 to apo B-containing lipoproteins, per ml, per hour. All samples were processed in the same assay.

Determination of lipoprotein associated phospholipase A2 activity
Lipoprotein associated phospholipase A2 activity (Lp-PLA2) was evaluated employing the radiometric assay described by Blank et al[15] with minor modifications.
| Patients with celiac disease | Control subjects | P |
|-----------------------------|------------------|---|
| **Age (yr)** | 50 (25-58) | 47 (28-60) | ns |
| **Men/woman** | 5/15 | 5/15 | ns |
| **BMI (kg/m²)** | 22.8 (20.4-26.2) | 23.0 (21.0-24.7) | ns |
| **Glucose (mg/dL)** | 87 ± 11 | 86 ± 12 | ns |
| **Insulin (mU/L)** | 7.2 (5.0-11.3) | 4.6 (2.6-6.7) | < 0.05 |
| **HOMA-IR** | 1.45 (1.04-2.24) | 1.00 (0.51-1.45) | < 0.05 |
| **QUICKI** | 0.33 (0.28-0.40) | 0.42 (0.34-0.65) | < 0.05 |
| **Urea (mg/dL)** | 27 (21-34) | 35 (34-39) | < 0.01 |
| **Creatinine (mg/dL)** | 0.74 (0.63-0.88) | 0.80 (0.75-1.10) | < 0.05 |
| **Uric acid (mg/dL)** | 5.0 ± 1.2 | 4.3 ± 1.6 | ns |
| **Bilirubin (mg/dL)** | 0.7 (0.5-0.8) | 0.6 (1.6-0.8) | ns |
| **ASAT (U/L)** | 26 (20-35) | 14 (12-20) | < 0.01 |
| **ALAT (U/L)** | 22 (17-39) | 18 (16-22) | ns |
| **ALP (U/L)** | 80 (59-102) | 124 (67-219) | ns |

BMI: Body mass index; HOMA-IR: Homeostasis Model Assessment insulin resistance; QUICKI: Quantitative insulin sensitivity check index; ASAT: Aspartate-amine transferase; ALAT: Alanine-amine transferase; ALP: Alkaline phosphatase; ns: Non significant. Data are shown as mean ± SD or median (interquartile range) according to data distribution.

The extraction of the marked acetate was performed using chloroform and the radioactivity of the aqueous phase was measured in a liquid scintillation counter (Packard 210 TR, Packard Instruments, Meridians, CT, United States). The radioactivity of the reaction buffer was also measured. Results were expressed as µmol of acetate liberated, per millilitre, per hour. All samples were processed in the same assay.

**Statistical analysis**

The sample size was calculated based on previous studies carried out in our laboratory. The outcome variables chosen to perform the sample size calculation for this study were HDL-C, CETP and Lp-PLA2. Having defined a 0.8 power, an effect size of 1.0 and a significance level of 0.05, the number of patients to be included in the present study was at least 17. Data distribution was analyzed with the Shapiro-Wilk test and data was expressed as mean ± SD, if distribution was found to be parametric, or as median (interquartile range) if distribution was non-parametric. To assess differences between groups, both parametric and non-parametric methods were employed. Correlation analyses were performed using Spearman or Pearson tests depending on variable distribution. When partial correlations, linear regressions or adjusted group differences were performed, all non-parametric variables were normalized prior to be included in the analysis. Statistical significance was defined as P < 0.05. A statistical review of the study was performed by a biomedical statistician. For the statistical analysis, the programs Infostat (Universidad Nacional de Cordoba, Argentina) and SPSS 19.0 (IBM, Chicago, United States) were used.

**RESULTS**

As expected, CD patients and control subjects did not show any difference in age, sex distribution and BMI (Table 1). Nevertheless, CD patients had significantly higher insulin levels and HOMA-IR, as well as lower QUICKI (Table 1). Both urea and creatinine concentrations were lower in the patient group, though individual results were comprised within the reference values. Additionally, ASAT activity was significantly increased in patients compared to controls.

The evaluation of hematological parameters showed no significant decrease in hemoglobin concentration in patients. Furthermore, only one woman met the criteria for anemia diagnosis (hemoglobin < 12 g/dL for women and < 13 g/dL for men). Similarly, there were no differences in total iron content, transferrin saturation or concentrations of ferritin, transferrin and vitamin B12. Only folic acid concentration was found to be significantly lower in patients (Table 2). Employing the reference values established by the World Health Organization[16,17], the prevalence of folic acid deficiency resulted to be 10% (< 4 ng/dL), of iron deficiency 15% (ferritin < 15 ng/dL) and of low vitamin B12 7.5% (< 203 pg/mL).

Regarding the lipid and lipoprotein profile, no differences were detected in TG, TC, LDL-C and apo B levels. However, statistically significant decreases in HDL-C and apo A-I concentrations were observed (Table 3). Furthermore, both parameters showed a strong positive correlation between them (r = 0.78; P < 0.0001). TC/HDL-C and apo B/apo A-I ratios, both of which possess high predictive value for CVD, were significantly higher in patients, whilst TG/HDL-C showed no difference between groups. On the other hand, CETP activity was similar in patients and controls (145% ± 32%/mL.h vs 132% ± 33%/mL.h, P > 0.05) and exhibited direct correlations with TG levels (r = 0.52; P < 0.005) and apo B/apo A-I ratio (r = 0.48; P < 0.005), and negative ones with HDL-C (r = -0.58; P < 0.0001) and apo A-I (r = -0.40; P < 0.005).

---

**Table 1 Clinical and biochemical characteristics from patients with celiac disease and control subjects**

| Variable          | Patients with celiac disease | Control subjects | P  |
|-------------------|-----------------------------|------------------|---|
| **Age (yr)**      | 50 (25-58)                  | 47 (28-60)       | ns |
| **Men/woman**     | 5/15                        | 5/15             | ns |
| **BMI (kg/m²)**   | 22.8 (20.4-26.2)            | 23.0 (21.0-24.7) | ns |
| **Glucose (mg/dL)** | 87 ± 11                     | 86 ± 12          | ns |
| **Insulin (mU/L)** | 7.2 (5.0-11.3)              | 4.6 (2.6-6.7)    | < 0.05 |
| **HOMA-IR**       | 1.45 (1.04-2.24)            | 1.00 (0.51-1.45) | < 0.05 |
| **QUICKI**        | 0.33 (0.28-0.40)            | 0.42 (0.34-0.65) | < 0.05 |
| **Urea (mg/dL)**  | 27 (21-34)                  | 35 (34-39)       | < 0.01 |
| **Creatinine (mg/dL)** | 0.74 (0.63-0.88) | 0.80 (0.75-1.10) | < 0.05 |
| **Uric acid (mg/dL)** | 5.0 ± 1.2                   | 4.3 ± 1.6        | ns |
| **Bilirubin (mg/dL)** | 0.7 (0.5-0.8)              | 0.6 (1.6-0.8)    | ns |
| **ASAT (U/L)**    | 26 (20-35)                  | 14 (12-20)       | < 0.01 |
| **ALAT (U/L)**    | 22 (17-39)                  | 18 (16-22)       | ns |
| **ALP (U/L)**     | 80 (59-102)                 | 124 (67-219)     | ns |

BMI: Body mass index; HOMA-IR: Homeostasis Model Assessment insulin resistance; QUICKI: Quantitative insulin sensitivity check index; ASAT: Aspartate-amine transferase; ALAT: Alanine-amine transferase; ALP: Alkaline phosphatase; ns: Non significant. Data are shown as mean ± SD or median (interquartile range) according to data distribution.

**Table 2 Hematological parameters from patients with celiac disease and control subjects**

| Variable          | Patients with celiac disease | Control subjects | P  |
|-------------------|-----------------------------|------------------|---|
| **Erythrocytes (10¹²/mL)** | 4.40 ± 0.48                | 4.58 ± 0.27      | ns |
| **Hematocrite (%)** | 38.5 ± 4.0                  | 40.1 ± 2.6       | ns |
| **Hemoglobin (g/dL)** | 13.0 ± 1.4                  | 13.3 ± 0.9       | ns |
| **Serum iron (µg/dL)** | 73 ± 35                     | 105 ± 61         | ns |
| **Ferritin (ng/mL)** | 33 (13-110)                 | 92 (43-117)      | ns |
| **Transferrin (mg/dL)** | 261 ± 62                    | 293 ± 59         | ns |
| **Transferrin Sat. (%)** | 25 ± 14                     | 29 ± 14          | ns |
| **Vitamin B12 (pg/mL)** | 337 (251-482)               | 315 (265-393)    | ns |
| **Folic acid (ng/mL)** | 5.4 (4.4-7.9)               | 12.2 (8.0-14.2)  | < 0.01 |

ns: Non significant; Sat.: Saturation. Data are shown as mean ± SD or median (interquartile range) according to data distribution.
Table 3  Lipid, lipoprotein and apolipoprotein profile from patients with celiac disease and control subjects

|                      | Patients with celiac disease (n = 20) | Control subjects (n = 20) | P     |
|----------------------|--------------------------------------|--------------------------|-------|
| TG (mg/dL)           | 81 (65-119)                          | 78 (60-114)              | ns    |
| TC (mg/dL)           | 185 ± 37                             | 194 ± 39                 | ns    |
| VLDL-C (mg/dL)       | 18 ± 8                               | 17 ± 7                   | ns    |
| LDL-C (mg/dL)        | 139 (89-149)                         | 107 (95-147)             | ns    |
| HDL-C (mg/dL)        | 45 ±15                               | 57 ±17                   | <0.05 |
| Non-HDL-C (mg/dL)    | 153 (105-167)                        | 137 (112-167)            | ns    |
| Apo A-I (mg/dL)      | 130 ± 31                             | 155 ± 29                 | <0.05 |
| Apo B (mg/dL)        | 93.6 ± 23.8                          | 83.5 ± 20.7              | ns    |
| TG/HDL-C             | 2.09 (1.13-2.98)                     | 1.29 (1.06-1.93)         | ns    |
| TC/HDL-C             | 4.19 (3.11-5.08)                     | 3.52 (2.84-4.08)         | <0.05 |
| ApoB/apo A-I         | 0.75 ± 0.25                          | 0.55 ± 0.16              | <0.01 |

TG: Triglycerides; TC: Total cholesterol; VLDL: Very low density lipoprotein; LDL: Low density lipoprotein; HDL: High density lipoprotein; apo: Apolipoprotein; ns: Non significant. Data are shown as mean ± SD or median (interquartile range) according to data distribution.

Evaluation of inflammation markers showed an increase in hsCRP levels in CD patients (Figure 1), which also correlated with apo B/apo A-I ratio (r = 0.42; P < 0.01). Even though white blood cell count (WBC) showed no differences between the two groups (6.11 ± 1.31 10^3/mL vs 6.17 ± 1.15 10^3/mL), it was directly associated with several parameters of the lipid profile (r/p; TG, 0.33/< 0.05; HDL-C, -0.34/< 0.05; apo B, 0.42/< 0.05; TG/HDL-C, 0.37/< 0.05; TC/HDL-C, -0.44/< 0.01; and apo B/apo A-I, 0.51; < 0.005). Lastly, Lp-PLA2 activity was similar between patients and controls (7.20 ± 1.28 µmol/mL.h vs 7.91 ± 2.02 µmol/mL.h) and was positively associated with LDL-C, main carrier of the enzyme in circulation (r = 0.50; P < 0.005).

Moreover, folic acid level was significantly associated with several parameters of the lipid profile (r/p; HDL-C, 0.52/< 0.05; apo A-I, 0.45/< 0.01; TG/HDL-C, -0.36/< 0.05; and apo B/apo A-I, -0.34/< 0.05) and with hsCRP concentration (r = -0.42; P < 0.05).

When comparing patients according to the clinical features, no differences were detected between patients with typical and atypical presentation of the disease in any of the parameters analyzed (data not shown).

**DISCUSSION**

Patients with CD showed a slight alteration in carbohydrate metabolism, decreased folic acid levels, a more atherogenic lipoprotein profile and an increase in the inflammatory marker hsCRP, with no difference evidenced between typical and atypical presentation of the disease. Likely, in both groups, the severity of duodenal lesion would not be a determining factor in the metabolic alterations nor in the increase of hsCRP observed in this study.

Unlike other pathologies characterized by the presence of systemic inflammation, such as lupus erythematosus and rheumatoid arthritis, in which patients show higher CVD morbidity and mortality[18,19], available evidence for CD appears less solid and more controversial. Even though some studies have described an increase in CVD risk compared with the general population[20–22], this has not been the case in other reports[4,23]. A group of CD patients, retrospectively studied in comparison with data from general population[24], showed less CVD risk employing the Framingham score. Nevertheless, assessment of cardiac functionality, specifically of the left ventricle[25], and the study of the presence of subclinical atherosclerosis, analyzed through aortic stiffness, aortic strain, and aortic distensibility[26,27], evidenced a clear association between CD and CVD. Moreover, a previous study showed higher carotid intima media thickness (an established marker of generalized atherosclerosis that correlates with the extent of coronary artery disease and predicts future cardiovascular events) in CD patients compared to healthy controls and similar to that of patients with type 1 diabetes[28]. Lastly, it is worth noting that a recent meta-analysis[29], based on ten studies performed in CD patients, showed a slight increase in the risk of stroke, acute myocardial infarction, and cardiovascular death, though only in the first case this increase reached statistical significance. As evidenced by the bibliography, the subject remains highly controversial.

In CD patients, a systemic pro-inflammatory status was evidenced through an increase in plasma hsCRP levels. According to the guides of the American Heart Association[30], values above 3 mg/dL, such as those observed in the group of the CD patients studied, would be indicative of high CVD risk. Even though Lp-PLA2 activity, considered a specific marker of vascular inflammation[31], showed no differences between patients and controls, there is solid evidence about the increase of other inflammation markers in CD. In this regard, a previous study reported an increase in tumor necrosis factor (TNF)-α-producing innate lymphoid cells in the intestinal mucosa of untreated CD patients in comparison with treated patients and healthy controls[32].
Moreover, an increase in TNF-α and interleukin (IL)-6 levels has been reported in the epithelium and the lamina propria of the intestinal mucosa of untreated CD patients. Additionally, higher levels of IL-6 have been observed in the plasma of untreated CD patients compared to treated ones and healthy controls. Regarding markers of carbohydrate metabolism, even though insulin levels and HOMA-IR were increased and QUICKI diminished, the analysis of the individual values did not allow the diagnosis of insulin resistance in any of the patients included in the present study. In fact, the results obtained were below the values reported for patients with metabolic syndrome or type 2 diabetes, though above those reported for the general population. Nevertheless, even the presence of a subtle alteration in carbohydrate metabolism in untreated CD patients would possess great clinical impact. Actually, GFD, the only available treatment for CD, contains higher caloric density than similar diets based on gluten containing foods, and its implementation could, as a result, increase the risk of developing obesity, and, consequently, metabolic syndrome and diabetes. Therefore, assessment of fasting glucose and insulin in patients diagnosed with CD before and during the introduction of GFD should be performed. However, the subject is still controversial. Kabbani et al. reported lower prevalence of metabolic syndrome and type 2 diabetes in patients under GFD treatment, regardless of treatment duration. Moreover, experiments carried out in C57BL/6 mice fed on a hyper fat diet with and without gluten showed that GFD reduced insulin resistance, adiposity and inflammation, although it is necessary to consider that these mice did not present CD. In the present study, the finding of significantly higher insulin levels and HOMA-IR and lower QUICKI than in controls suggests the presence of a slightly altered carbohydrate metabolism, which could be related to the pro-inflammatory status described in CD patients and evidenced in our study by higher hsCRP levels. It has been previously proposed that inflammation could be a causative agent for alterations in carbohydrate metabolism through the action of cytokines such as TNF-α, IL-6 and IL-1β, among others.

Studying lipoprotein profile in CD patients appears interesting, since there is evidence for both a decrease in cholesterol absorption and an increase in its synthesis. In the current study, patients showed TC and LDL-C levels similar to controls. These findings are in disagreement with the decrease in both parameters previously reported for CD patients. Patients evaluated in this study also presented lower HDL-C levels. There is prior evidence showing a 12% prevalence of CD in patients with low HDL-C concentration, much higher than that reported for the general population, which implies a causal relationship between the presence of CD and the decrease in HDL-C. Unlike in the case of patients with insulin resistance, this decrease was not found to be associated with higher CETP activity. Therefore, this alteration could result from a lower synthesis and secretion of apo A-I. Furthermore, longitudinal studies described an increase in HDL-C and apo A-I values after initiation of treatment with GFD. In addition, CD patients presented an increase in TC/HDL-C and apo B/apo A-I ratios, which reflect an imbalance between proatherogenic and antiatherogenic lipid factors. Another possibility that could explain HDL-C decrease is that HDL particles from CD patients would possess less capability to promote cholesterol efflux from cells. In fact, apo A-I has not only got a structural role in HDL particles, but it is also involved in multiple antiatherogenic functions including cholesterol efflux promotion. Due to the decrease in intestinal apo A-I synthesis, the number of circulating HDL particles would be diminished and, in turn, each particle would be depleted in this apolipoprotein. As a matter of fact, in other inflammatory pathologies such as rheumatoid arthritis, alterations in HDL functionality have been associated with higher risk of CVD. Study of HDL functions in affected patients could provide important evidence linking CD and CVD risk.

Regarding hematological parameters, only folic acid was decreased in CD patients. This finding is consistent with previous reports that show a decrease in folic acid levels as a consequence of impaired intestinal absorption, resulting from the damage to the intestinal epithelium caused by the inflammatory process. This folic acid deficiency persists, in many cases, even after the initiation of treatment with GFD. It is worth noting that a decrease in folic acid levels may lead to an increase in homocysteine concentration. One of the main homocysteine clearance pathways consists of its re-methylation and recycling to methionine, a process catalyzed by the methionine synthase (MTR) enzyme, which links the folate cycle with homocysteine metabolism. In fact, different studies showed higher homocysteine levels in CD patients, and this increment was independently associated with increased risk and severity of coronary artery disease. Moreover, high homocysteine levels were also identified as independent predictors of a suboptimal response to antiplatelet therapy with acetyl salicylic acid, thus favouring thrombotic complications in patients with coronary artery disease. In addition, in a meta-analysis of randomized controlled trials, Liu et al. demonstrated that folic acid supplementation could improve the endothelial dysfunction observed in patients with coronary artery disease. Nevertheless, studies on homocysteine-lowering interventions with vitamin B6, folic acid (vitamin B9) or vitamin B12, administrated alone or in combination with the purpose of preventing cardiovascular events, failed to consistently demonstrate their efficacy. Therefore, consideration of increased homocysteine levels as a risk factor for CVD is still a controversial topic.

In the present study, newly diagnosed CD patients, who were not following a GFD, presented higher insulin...
levels, HOMA-IR index, apo B/apo A-I ratio and hsCRP concentration, as well as lower QUICKI index, HDL-C and apo A-I levels in comparison with sex and age-matched healthy controls.

Limitations
The main limitation of the present study is that, due to its cross-sectional design, it only provides a “snapshot” of the outcome and the characteristics associated with it, at a specific point in time. Then, only associations that may exist and are therefore useful in generating hypotheses for future research may be established. Another limitation is the sample size, which may be attributed to the fact that this study only included newly diagnosed CD patients, but that hampered the search for a possible correlation between intestinal inflammation factors and the risk of atherosclerosis.

Conclusions
According to the results reported in the current study, untreated CD patients would present modifications in carbohydrate and lipoprotein metabolism and a pro-inflammatory status. Even though the magnitude of the alterations here described is not major, their presence and interaction through long periods of time in a chronic pathologic condition, as it is the case with CD, would constitute a high risk of developing atherosclerotic CVD.

COMMENTS

Background
Celiac disease (CD) is a multisystemic disease which main trait is chronic and diffuse inflammation of the mucosa of the small intestine. The only available therapy for CD consists of the implementation of a gluten free diet (GFD). It is well known that CD patients do not show classical cardiovascular disease (CVD) risk factors suggesting that CD would be associated with novel atherogenic risk factors or even with other non-identified risk factors such as inflammatory markers.

Research frontiers
The role of novel atherogenic risk factors or inflammatory markers for CVD in CD patients has been poorly studied. The research hotspot is to assess which factors or markers for cardiovascular disease are found in CD patients in order to be able to prevent of treat them.

Innovations and breakthroughs
It is well known that CD patients do not show classical CVD risk factors. Therefore in these patients, detection of novel atherogenic risk factors would be crucial to reduce the risk of CVD.

Applications
The detection of CVD risk factors in CD patients is an important tool for the implementation of an adequate treatment.

Terminology
CD is a disease which mainly affects the digestive system. Its main trait is chronic and diffuse inflammation of the mucosa of the small intestine and it can present a wide variety of clinical symptoms. It is remarkable that most cases of CD lack typical gastrointestinal symptoms and are, instead, very frequently associated with presentations known as atypical or extra-intestinal. Thus, its diagnosis represents one of the main challenges for health professionals

Peer-review
This is an interesting study showing that patients with CD do have an atherogenic lipoprotein profile that may dispose them to develop CVD.

REFERENCES

1. Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nut Rev Gastroenterol Hepatol 2010; 7: 204-213 [PMID: 20212505 DOI: 10.1038/norgastro.2010.23]
2. Katz KD, Rashitak S, Lahr BD, Melton LJ, Krause PK, Maggi K, Talley NJ, Murray JA. Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms. Am J Gastroenterol 2011; 106: 1333-1339 [PMID: 21364545 DOI: 10.1038/ajg.2011.21]
3. Armstrong MJ, Hegade VS, Robins G. Advances in coeliac disease. Curr Opin Gastroenterol 2012; 28: 104-112 [PMID: 22123644 DOI: 10.1097/MOG.0b013e32834d0844]
4. West J, Logan RF, Carol TR, Smith C, Hubbard R. Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study. Aliment Pharmacol Ther 2004; 20: 73-79 [PMID: 15225173 DOI: 10.1111/j.1365-2036.2004.02008]
5. Lewis NR, Sanders DS, Logan RF, Fleming KM, Hubbard RB, West J. Cholesterol profile in people with newly diagnosed celiac disease: a comparison with the general population and changes following treatment. Br J Nutr 2009; 102: 509-513 [PMID: 19660152 DOI: 10.1017/S0007070409297248]
6. Ludwigsson JF, de Faire U, Ekborn A, Montgomery SM. Vascular disease in a population-based cohort of individuals hospitalised with celiac disease. Heart 2007; 93: 1111-1115 [PMID: 17277354 DOI: 10.1136/hrt.2006.097097]
7. Leffler DA, Green PH, Fasano A. Extraintestinal manifestations of celiac disease. Nut Rev Gastroenterol Hepatol 2015; 12: 561-571 [PMID: 26260366 DOI: 10.1038/ajgastro.2015.131]
8. Meredo T, Dauteville C, Tetzlaff W, Martin M, Botta E, Lhomme M, Saez MS, Sorroche P, Boero L, Arbelside J, Chapman MJ, Kontush A, Biffes F. Oxidative stress, HDL functionality and effects of intravenous iron administration in women with iron deficiency anemia. Clin Nutr 2017; 36: 552-558 [PMID: 26926576 DOI: 10.1136/clinch.2016.02003]
9. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138 [PMID: 19942084 DOI: 10.1016/j.jacc.2009.09.009]
10. Bonora E, Tagher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauini T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63 [PMID: 10857969]
11. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2003; 26: 2426-2432 [PMID: 12882874]
12. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388 [PMID: 7074948]
13. Assmann G, Jabs HU, Kohne U, Nolte W, Schriewer H. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clin Chem Acta 1984; 140: 77-83 [PMID: 6744629]
14. Lagrost L, Gandjini H, Athias A, Guyard-Dangremont V, Lallemant C, Gambert P. Influence of plasma cholesterol ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb 1993; 13: 815-825 [PMID: 8499401]
15. Blank ML, Hall MN, Cress EA, Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochim Biophys Acta
World Health Organization. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations [database on the Internet]. 2016. [accessed 2016 Mar 30]. Available from: http://www.who.int/vmnis/indicators/serum_ferritin.pdf

World Health Organization. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies [database on the Internet]. 2016. [accessed 2016 Mar 30]. Available from: http://www.who.int/vmnis/indicators/en/

Avinä-Zubeta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacalle D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-1697 [PMID: 19035439 DOI: 10.1002/art.24092]

Hak AE, Karwoski EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheum 2009; 61: 1396-1402 [PMID: 19790130 DOI: 10.1002/art.24537]

Jansen S, Bhangu J, de Rooij S, Daams J, Kenny RA, van der Velde N. The Association of Cardiovascular Disorders and Falls: A Systematic Review. J Am Med Dir Assoc 2016; 17: 193-199 [PMID: 26455926 DOI: 10.1016/j.jamda.2015.08.022]

Ludvigsson JF, James S, Asling J, Stenestrand U, Ingelsson E, National cohort study of risk of ischaemic heart disease in patients with celiac disease. Circulation 2011; 123: 483-490 [PMID: 21262996 DOI: 10.1161/CIRCULATIONAHA.110.965624]

Wei L, Spier S, Reynolds N, Walsh S, Fahey T, MacDonald TM. The association between coeliac disease and cardiovascular disease. Aliment Pharmacol Ther 2008; 27: 514-519 [PMID: 18162081 DOI: 10.1111/j.1365-2036.2007.03594.x]

Whorrell PJ, Alderson MR, Foster KJ, Wright R. Death from ischaemic heart-disease and malignancy in adult patients with coeliac disease. Lancet 1976; 2: 113-114 [PMID: 59182]

Stein AC, Liao C, Paski S, Polonsky T, Semrad CE, Kupfer SS. Obesity and Cardiovascular Risk in Adults With Celiac Disease. J Clin Gastroenterol 2016; 50: 545-550 [PMID: 26444464 DOI: 10.1097/MCG.0000000000000422]

Akin FE, Sari C, Ozer-Sari S, Demirel-Bolat A, Durum T, Keles T, Ersoy O, Bozkurt E. The evaluation of left ventricular functions with tissue doppler echocardiography in adults with celiac disease. Saudi J Gastroenterol 2015; 22: 116-121 [PMID: 26997217 DOI: 10.4103/1319-3767.164187]

Korkmaz H, Sozen M, Kebapcilar L. Increased arterial stiffness and its relationship with inflammation, insulin, and insulin resistance in celiac disease. Eur J Gastroenterol Hepatol 2015; 27: 1193-1199 [PMID: 26118110 DOI: 10.1111/ejh.12633]

Sari S, Dogu F, Hwa V, Haskologlu S, Dauber A, Rosenfeld SS, Polat M, Kaloglu Z, Kausan A, Daligc B, Ikincigullari A. A successful HSCT in a Girl with Novel LRBA Mutation with Refractory Celiac Disease. J Clin Immunol 2016; 36: 8-11 [PMID: 26686526 DOI: 10.1007/s10875-015-0220-y]

Pitocco D, Giubilato S, Martini F, Zaccardi F, Pazzano V, Manto A, Cammarota G, Di Stasio E, Pedicino D, Liuzzo G, Crea F, Tortora R, Caporaso N, Rispo A. Metabolic syndrome in children with celiac disease: results from the nurses’ health study. Am J Cardiol 2005; 96: 399-404 [PMID: 16054467 DOI: 10.1016/j.amjcard.2005.03.085]

Radzuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2008; 93: 135-141 [PMID: 14715840 DOI: 10.1210/jcem.85.12.7025]

Skrha J, Haas T, Sindelka G, Prázný M, Widimský J, Cibula D, Svacina S. Comparison of the insulin action parameters from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419 [PMID: 3989925]

McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Watters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399-404 [PMID: 16054467 DOI: 10.1016/j.amjcard.2005.03.085]

Kaufkien K, Lindors KL, Collin P, Koskinen O, Mäki M. Celiac disease—a diagnostic and therapeutic challenge. Clin Chem Lab Med 2010; 48: 1205-1216 [PMID: 20578966 DOI: 10.1515/CCLM.2010.241]

Norsa L, Shin RJ, Vesti N, Verduci E, Hartman C, Ghisleni D, Riva E, Giovannini M. Cardiovascular disease risk factor profiles in children with celiac disease on gluten-free diets. World J Gastroenterol 2013; 19: 5658-5664 [PMID: 24039358 DOI: 10.3748/wjg.v19.i34.5658]

Kabbani TA, Kelly CP, Betensky RA, Hansen J, Pallav K, Villafuerte-Gálvez JA, Vanga R, Mukherjee R, Novero A, Dennis M, Leffler DA. Patients with celiac disease have a lower prevalence of non-insulin-dependent diabetes mellitus and metabolic syndrome. Gastroenterology 2013; 144: 912-917.e1 [PMID: 23354016 DOI: 10.1053/j.gastro.2013.01.033]

Soares FL, de Oliveira Matoso R, Teixeira LG, Menezes Z, Pereira SS, Alves AC, Batista NV, de Faria AM, Cara DC, Ferreira AV, Alvarez-Leite JL. Gluten-free diet reduces adiposity, inflammation and insulin resistance associated with the induction of PPAR-alpha and PPAR-gamma expression. J Nutr Biochem 2013; 24: 1105-1111 [PMID: 23253599 DOI: 10.1016/j.jnutbio.2012.08.009]

Shoelson SE. Point-counterpoint: Interleukin-6 does/not have a 15731492 DOI: 10.1161/01.ATV.0000160531.21962.a7

Marafini I, Monteleone I, Di Fusco D, Cupi ML, Paulozzi OA, Colontani A, Ortenzi A, Izzo R, Vita S, De Luca E, Sica G, Pallone F, Monteleone G. TNF-a Producing Innate Lymphoid Cells (ILCs) Are Increased in Patients with Celiac Disease and Contribute to Promote Intestinal Atrophy in Mice. PLoS One 2015; 10: e0126291 [PMID: 25957071 DOI: 10.1371/journal.pone.0126291]

Iacomingo M, Marano A, Stililliano I, Auferio VR, Iaquinto G, Schettino M, Masucci A, Troncone R, Auricchio S, Mazzarella G. Celiac disease: role of intestinal compartments in the mucosal immune response. Mol Cell Biochem 2016; 411: 341-349 [PMID: 26541753 DOI: 10.1007/s11010-015-2596-7]

Przemsios RJ, Kontakou M, Nobili V, Ciclitira PJ. Raised pro-inflammatory cytokines interleukin 6 and tumour necrosis factor alpha in coeliac disease mucosa detected by immunohistochemistry. Gut 1994; 35: 1398-1403 [PMID: 8399194]

Kapoor A, Patwari AK, Kumar P, Jain A, Narayan S. Serum soluble interleukin-2 receptor, interleukin-6 and tumour necrosis factor alpha as markers of celiac disease activity. Indian J Pediatr 2013; 80: 108-113 [PMID: 22766904 DOI: 10.1007/s10916-011-0287-0]

Romaldini CC, Barbieri D, Okay TS, Raíz R, Cançado EL. Serum soluble interleukin-2 receptor, interleukin-6, and tumour necrosis factor-alpha levels in children with celiac disease: response to treatment. J Pediatr Gastroenterol Nutr 2002; 35: 513-517 [PMID: 12394376]

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419 [PMID: 3989925]

CVD risk in celiac disease

Tetzlaff WF et al. CVD risk in celiac disease

WJC | www.wjgnet.com

455

May 26, 2017 | Volume 9 | Issue 5
beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol (1985) 2007; 102: 820; author reply 825 [PMID: 17323463]

47 Shoelee SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801 [PMID: 16823477 DOI: 10.1172/JCI29069]

48 Vuoristo M, Kesäniemi YA, Gylling H, Miettinen TA. Metabolism of cholesterol and apolipoprotein B in celiac disease. Metabolism 1993; 42: 1386-1391 [PMID: 8231831]

49 Vuoristo M, Miettinen TA. Cholesterol absorption, elimination and synthesis in celiac disease. Eur J Clin Invest 2012; 42: 285-291 [PMID: 22867774]

50 Medine S, Hakem S, Bard JM, Modjaoui I, Benhamamouch S, Lebel P, Fruchart JC, Clavey V. Serum lipoprotein profile in Algerian patients with celiac disease. Clin Chim Acta 1995; 235: 189-196 [PMID: 7554273]

51 Capristo E, Malandrino N, Farnetti S, Mingrone G, Leggio L, Addolorato G, Gasbarrini G. Increased serum high-density lipoprotein-cholesterol concentration in celiac disease after gluten-free diet treatment correlates with body fat stores. J Clin Gastroenterol 2009; 43: 946-949 [PMID: 19809359 DOI: 10.1097/MCG.0b013e3181978e4d]

52 Medine S, Hakem S, Bard JM, Modjaoui I, Benhamamouch S, Lebel P, Fruchart JC, Clavey V. Serum lipoprotein profile in Algerian patients with celiac disease. Clin Chim Acta 1995; 235: 189-196 [PMID: 7554273]

53 Capristo E, Addolorato G, Mingrone G, Scarfone A, Greco AV, Gasbarrini G. Low-serum high-density lipoprotein-cholesterol concentration as a sign of celiac disease. Am J Gastroenterol 2000; 95: 3331-3332 [PMID: 11095384 DOI: 10.1111/j.1572-0241.2000.03329.x]

54 Borrugge SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 1051-1069 [PMID: 14636288]

55 Florén CH, Alm P. Defective synthesis of apolipoprotein A-I in jejunal mucosa in coeliac disease. Scand J Gastroenterol 1988; 23: 856-860 [PMID: 3067329]

56 Rao SN, Magill PJ, Miller NE, Lewis B. Plasma high-density lipoprotein metabolism in subjects with primary hyperglycemia: altered metabolism of apoproteins A1 and AII. Clin Sci (Lond) 1980; 59: 359-367 [PMID: 7428302]

57 McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S. Lipids, lipoproteins, and apolipoproteins as risk factors of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-233 [PMID: 18640459 DOI: 10.1016/S0140-6736(08)61076-4]

58 Vedhachalam C, Liu L, Nickel M, Dhanasekaran P, Anantharamaiah GM, Lund-Katz S, Rothblat GH, Phillips MC. Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids. J Biol Chem 2004; 279: 49931-49939 [PMID: 15383537 DOI: 10.1074/jbc.M400624200]

59 Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012; 71: 1157-1162 [PMID: 22267330 DOI: 10.1136/annrheumdis-2011-200493]

60 García-Manzanares A, Luendo AJ. Nutritional and dietary aspects of celiac disease. Nutr Clin Pract 2011; 26: 163-173 [PMID: 21447770 DOI: 10.1177/0884533611439977]

61 Caruso R, Pallone F, Stasi E, Romeo S, Monteleone G. Appropriate nutrient supplementation in celiac disease. Ann Med 2013; 45: 522-531 [PMID: 24195595 DOI: 10.3109/07873390.2013.849383]

62 Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis 2011; 34: 75-81 [PMID: 20814827 DOI: 10.1007/s10545-010-9177-4]

63 Dickey W, Mason MT, Whitle CR, Kelly MT, Pentieva K, Horigan G, Patton S, McNulty H. Homocysteine and related B-vitamin status in coeliac disease: Effects of gluten exclusion and histological recovery. Scand J Gastroenterol 2008; 43: 682-688 [PMID: 18569985 DOI: 10.1080/00365520701881118]

64 Saibeni S, Lecci A, Meucci G, Cattaneo M, Tagliaab L, Rondonetti E, Formenti S, De Franchis R, Vecchi M. Prevalence of hyperhomocysteinemia in adult gluten-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. Clin Gastroenterol Hepatol 2005; 3: 574-580 [PMID: 15952099]

65 Schaffer A, Verdia M, Cassetti E, Marino P, Suryapranata H, De Luca G. Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. Thromb Res 2014; 134: 288-293 [PMID: 24928335 DOI: 10.1016/j.thromres.2014.05.025]

66 Verdoia M, Schaffer A, Pergolini P, Rolla R, Barbieri L, Bellomo G, Sinigaglia F, Marino P, Suryapranata H, De Luca G. Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid. J Cardiovasc Pharmacol 2015; 66: 35-40 [PMID: 25714953 DOI: 10.1097/JCP.0000000000000240]

67 Liu Y, Tian T, Zhang H, Gao L, Zhou X. The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials. Atherosclerosis 2014; 235: 31-35 [PMID: 24814647 DOI: 10.1016/j.atherosclerosis.2014.03.032]

68 Marti-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015; 1: CD006612 [PMID: 25590290 DOI: 10.1002/14651858.CD006612.pub4]

69 Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015; 14: 6 [PMID: 25577237 DOI: 10.1186/1475-2891-14-6]

P- Reviewer: Holmes GKT, Pallav K  S- Editor: Ji FF  L- Editor: A  E- Editor: Wu HL
